- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04522986
An Exploratory Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection (COVID-19)
March 16, 2021 updated by: Rohto Pharmaceutical Co., Ltd.
Safety and efficacy of ADR-001 are evaluated in Patients with Severe Pneumonia caused by SARS-CoV-2 infection.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
Patients with Severe Pneumonia caused by SARS-CoV-2 infection are enrolled to the study.
Adipose-derived mesenchymal stem cells (AD-MSCs) are administered once a week, total four times intravenously.
Safety and efficacy of AD-MSCs are evaluated for 12 weeks after first administer.
Study Type
Interventional
Enrollment (Actual)
6
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Osaka
-
Suita, Osaka, Japan, 565-0871
- Osaka University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- SARS-CoV-2 infection is confirmed on antigen test or PCR test
- Pulmonary infiltrative shadow is confirmed on chest X-ray test
- Mechanical ventilation is being utilized, or Acute Respiratory Failure whose PaO2 is not being achieved to 80 mmHg in spite of High-flow oxygen therapy
Exclusion Criteria:
- Continue treatment for Pneumonia before SARS-CoV-2 infection
- SOFA score >= 15
- Infection type on DIC diagnosis criteria >= 4
- Deep Venous Thrombosis
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Mesenchymal stem cell
4 times dose of Mesenchymal stem cell
|
1*10^8 cells are administered once a week, total four times intravenously.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety: Adverse Event
Time Frame: 12 weeks
|
Adverse events which appear in subjects with ADR-001 treatment are evaluated.
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Yuji Fujino, MD, Osaka University Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
August 21, 2020
Primary Completion (ACTUAL)
February 2, 2021
Study Completion (ACTUAL)
February 2, 2021
Study Registration Dates
First Submitted
August 20, 2020
First Submitted That Met QC Criteria
August 20, 2020
First Posted (ACTUAL)
August 21, 2020
Study Record Updates
Last Update Posted (ACTUAL)
March 18, 2021
Last Update Submitted That Met QC Criteria
March 16, 2021
Last Verified
March 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ADR-001-1919
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Severe Acute Respiratory Syndrome Coronavirus 2
-
TakedaCompletedPrevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)Japan
-
Oneness Biotech Co., Ltd.CompletedDisease Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (Disorder)United States
-
Saint Francis CareCompletedSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | COVID | CoronavirusUnited States
-
University Hospital, Basel, SwitzerlandCompletedSevere-Acute-Respiratory-Syndrome-Coronavirus-2 (SARS-CoV-2)Switzerland
-
ANRS, Emerging Infectious DiseasesRecruitingSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)France, Martinique
-
University of PecsHungarian Ministry of Innovation and TechnologyTerminatedSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Hungary
-
Cogna Technology Solutions LLCNovavaxCompletedSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)United Arab Emirates
-
Pulmoquine Therapeutics, IncRockefeller UniversityCompletedSevere Acute Respiratory Syndrome Coronavirus 2United States
-
Goethe UniversityNationwide Network of University Medicine (NUM) on Covid-19RecruitingSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Germany
-
AbbVieCompletedSevere Acute Respiratory Syndrome - CoronaVirus 2 (SARS-CoV-2)United States
Clinical Trials on Mesenchymal stem cell
-
Mayo ClinicUniversity of Alabama at Birmingham; University of Mississippi Medical CenterCompletedChronic Kidney Disease | Renal Artery Stenosis | Ischemic Nephropathy | Renovascular DiseaseUnited States
-
Mayo ClinicCompletedBronchiolitis Obliterans | Lung Transplant RejectUnited States
-
Children's Hospital of Chongqing Medical UniversityUnknown
-
University of LiegeCompletedHematological MalignanciesBelgium
-
Royan InstituteCompletedOsteoarthritisIran, Islamic Republic of
-
Daping Hospital and the Research Institute of Surgery...Children's Hospital of Chongqing Medical University; Chongqing Maternal and...Withdrawn
-
Celal Bayar UniversityThe Scientific and Technological Research Council of Turkey; Acıbadem LabcellCompletedSkin Diseases | Immune System Diseases | Autoimmune Diseases | UrticariaTurkey
-
Children's Hospital of Chongqing Medical UniversityUnknownBronchopulmonary DysplasiaChina
-
Royan InstituteCompletedOsteoarthritisIran, Islamic Republic of
-
Samsung Medical CenterPharmicell Co., Ltd.UnknownStroke, IschemicKorea, Republic of